Why Nanobiotix Stock Is Soaring Monday
Portfolio Pulse from Adam Eckert
Nanobiotix S.A. (NASDAQ:NBTX) has entered into a license agreement with Janssen Pharmaceutical, a subsidiary of Johnson & Johnson (NYSE:JNJ), for the global co-development and commercialization of NBTXR3. Nanobiotix will receive cash and operational support valued at up to $60 million, including a licensing fee of $30 million. The company is also eligible for success-based payments of up to $1.8 billion and will receive royalties following commercialization.
July 10, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nanobiotix's agreement with Janssen Pharmaceutical could provide significant financial benefits and accelerate the development of NBTXR3.
The agreement with Janssen Pharmaceutical provides Nanobiotix with financial support and a global platform for the development and commercialization of NBTXR3. This could significantly boost the company's revenues and accelerate the development of NBTXR3, which is likely to have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Johnson & Johnson's subsidiary, Janssen Pharmaceutical, has entered into a license agreement with Nanobiotix for the global co-development and commercialization of NBTXR3.
While the agreement with Nanobiotix could potentially add a promising product to Janssen's portfolio, the financial impact on Johnson & Johnson, given its size and diverse portfolio, is likely to be limited in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50